DrugPatentWatch Database Preview
Try a free trial
See Plans and Pricing
« Back to Dashboard
Insulin aspart recombinantis the generic ingredient in five branded drugs marketed by Novo Nordisk Inc and is included in one NDA. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Insulin aspart recombinant has two hundred and twelve patent family members in twenty-two countries.
There are forty drug master file entries for insulin aspart recombinant. Six suppliers are listed for this compound.
Summary for insulin aspart recombinant
Pharmacology for insulin aspart recombinant
|Drug Class||Insulin Analog |
Medical Subject Heading (MeSH) Categories for insulin aspart recombinant
|Country||Patent Number||Estimated Expiration|
|Brazil||9906857||Try a Free Trial|
|Canada||2616248||Try a Free Trial|
|Poland||374182||Try a Free Trial|
|Czech Republic||297361||Try a Free Trial|
|Austria||483487||Try a Free Trial|
|Australia||2008213084||Try a Free Trial|
|China||1374876||Try a Free Trial|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|2498802||300883||Netherlands||Try a Free Trial||PRODUCT NAME: INSULIN GLARGINE/LIXISENATIDE; REGISTRATION NO/DATE: EU/1/16/1157 20170113|
|2107069||2013/034||Ireland||Try a Free Trial||PRODUCT NAME: INSULIN DEGLUDEC; NAT REGISTRATION NO/DATE: EU/1/12/807-001, 004, 005, 007-009, 012, 013 015 20130121|
|0885961||SPC/GB05/024||United Kingdom||Try a Free Trial||PRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929|
|0792290||0491022-0||Sweden||Try a Free Trial||PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN|
|0368187||C300019||Netherlands||Try a Free Trial||PRODUCT NAME: INSULINE GLARGINE,DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH GESCHIKT ZOUT; REGISTRATION NO/DATE: EU/1/00/134/001 - 007 20000609|
|2107069||C 2013 019||Romania||Try a Free Trial||PRODUCT NAME: INSULINA DEGLUDECIN TOATE FORMELE SALE ASA CUM SUNT PROTEJATE IN BREVETUL DEBAZA; NATIONAL AUTHORISATION NUMBER: EU/1/12/807/001; DATE OF NATIONAL AUTHORISATION: 20130121; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/807/001; DATE OF FIRST AUTHORISATION IN EEA: 20130121|
|2209800||1490067-4||Sweden||Try a Free Trial||PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.